It is a cell cycle-specific antitumor drug that inhibits the polymerization of intracellular tubulin, prevents the formation of spindles in the mitosis of proliferating cells, and stops cell division at the metaphase of mitosis. This product has a broad antitumor spectrum for transplanted animal tumors and has no complete cross-resistance with vinblastine and vincristine.

This product is the levorotatory form of ofloxacin, and its antibacterial activity is about 2 times that of ofloxacin. Its main mechanism of action is to inhibit bacterial DNA gyrase activity and inhibit bacterial DNA replication. It has the characteristics of broad antibacterial spectrum and strong antibacterial effect. It has strong antibacterial activity against most Enterobacteriaceae, such as Klebsiella pneumoniae, Proteus, Salmonella typhi, Shigella, influenza bacillus, some Escherichia coli, Pseudomonas aeruginosa, gonococci, etc. It also has good antibacterial effect against some Staphylococci, Streptococcus pneumoniae, Chlamydia, etc.

Intraperitoneal injection of the drug into mice with cholestatic jaundice induced by 1-naphthyl isothiocyanate can reduce the levels of serum alanine aminotransferase, aspartate aminotransferase and serum conjugated bilirubin, and alleviate liver cell damage in the model animals.

This product is a fluoroquinolone antibacterial drug with a broad-spectrum antibacterial effect, especially against aerobic Gram-negative bacteria. It acts on the A subunit of bacterial DNA helicase, inhibits DNA synthesis and replication, and causes bacterial death. It has effects on both Gram-positive and Gram-negative bacteria. Bacteria are not easy to develop resistance to this product, and there is no cross-resistance between similar drugs and antibiotics.

It has local analgesic effect and antiseptic effect